NCT02192463 - Relative Bioavailability of Different Oral Viramune Extended Release Formulations Compared to Viramune® Oral Suspension in Healthy Male Volunteers | Biotech Hunter

Enrollment

204

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

August 31, 2006

Conditions

Healthy

Interventions

DRUG

NVP ER 300 mg (KCR 20%) Medium Release

DRUG

NVP ER 300 mg (KCR 25%) Medium Release

DRUG

NVP ER 300 mg (KCR 30%) Slow Release

DRUG

NVP ER 400 mg (KCR 25%) Medium Release

DRUG

NVP ER 300 mg (KCR 40%) Slow Release

DRUG

NVP ER 300 mg (ECR 20%) Fast Release

DRUG

NVP ER 400 mg (KCR 20%) Medium Release

DRUG

NVP ER 400 mg (KCR 30%) Slow Release

DRUG

NVP ER 400 mg (KCR 40%) Slow Release

DRUG

NVP ER 400 mg (ECR 20%) Fast Release

DRUG

Nevirapine immediate release (IR) 200 mg